Stratatech Corp. won $3.95 million from the U.S. Dept. of Defense’s Armed Forces Institute of Regenerative Medicine.
The Madison, Wis.-based company said the AFIRM cash will fund the Phase IIb clinical trial of its StrataGraft cell-based, tissue-engineered skin substitute.
Stratatech designed the study to assess the efficacy of the graft as a true human skin replacement "in the healing of excised, deep, partial-thickness burns that otherwise would require skin grafting," according to a press release. Earlier clinical trials suggested that the StrataGraft is safe and effective for patients with third-degree burns and other "complex skin defects," according to the company.
“This phase of our StrataGraft clinical trial is a major step forward in our efforts to commercialize a product that should provide significant benefits to patients with severe burns, wounds and other traumatic skin injury. We look forward to working with our collaboration partners towards a successful clinical trial outcome,” CEO Lynn Allen-Hoffmann said in prepared remarks.
The skin substitute developer raised $3 million in an offering of debt, options, warrants and other securities in April to fund the clinical trial. Stratatech said it expects the study to start during the first half of 2011.